Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial Meeting Abstract
| Authors: | Kelsen, D.; Jhawer, M.; Ilson, D.; Tse, A.; Randazzo, J.; Robinson, E.; Capanu, M.; Shah, M. A. |
| Abstract Title: | Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial |
| Meeting Title: | 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 27 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2009 May 29-Jun 2 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2009-05-20 |
| Start Page: | 204s |
| Language: | English |
| ACCESSION: | WOS:000276606603103 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2009.27.15_suppl.4512 |
| Notes: | Meeting Abstract: 4512 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
